Nuvation Bio Inc. is trading 6.7% down at $4.60 in pre-market action as the stock undergoes consolidation following a sharp rally earlier in the week.
- The recent upward momentum was triggered by RBC Capital on June 9, 2026, when the firm issued an Outperform rating and a significant price-target hike to $20.
- Current weakness appears to be driven by profit-taking and market consolidation rather than any new company-specific developments.
- This pullback, which began on June 10, 2026, follows a period of heightened volatility and significant gains for the biotech firm.